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Jacob Hollenberg1,2, Jean-Louis Vincent3 and Leif Svensoon1,2Abstract
Background: Therapeutic hypothermia (TH, 32-34°C) has been shown to improve neurological outcome in comatose
survivors of out-of-hospital cardiac arrest (OHCA) with ventricular tachycardia or fibrillation. Earlier initiation of TH may
increase the beneficial effects. Experimental studies have suggested that starting TH during cardiopulmonary
resuscitation (CPR) may further enhance its neuroprotective effects. The aim of this study was to evaluate whether
intra-arrest TH (IATH), initiated in the field with trans nasal evaporative cooling (TNEC), would provide outcome benefits
when compared to standard of care in patients being resuscitated from OHCA.
Methods/design: We describe the methodology of a multi-centre, randomized, controlled trial comparing IATH
delivered through TNEC device (Rhinochill, Benechill Inc., San Diego, CA, USA) during CPR to standard treatment,
including TH initiated after hospital admission. The primary outcome is neurological intact survival defined as cerebral
performance category 1–2 at 90 days among those patients who are admitted to the hospital. Secondary outcomes
include survival at 90 days, proportion of patients achieving a return to spontaneous circulation (ROSC), the proportion
of patients admitted alive to the hospital and the proportion of patients achieving target temperature (<34°C) within
the first 4 hours since CA.
Discussion: This ongoing trial will assess the impact of IATH with TNEC, which may be able to rapidly induce brain
cooling and have fewer side effects than other methods, such as cold fluid infusion. If this intervention is found to
improve neurological outcome, its early use in the pre-hospital setting will be considered as an early neuro-protective
strategy in OHCA.
Trial registration: NCT01400373.
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Sudden cardiac death is one of the major health issues
of the industrialized world [1]. Despite decades of efforts
to promote cardiopulmonary resuscitation (CPR) educa-
tion and the introduction of automated external defibrilla-
tors, less than 50% of cardiac arrest (CA) victims achieve a
return of spontaneous circulation (ROSC) and this per-
centage drops to 20% or less for those patients that live in
rural areas or do not have an initial rhythm that can be* Correspondence: ftaccone@ulb.ac.be
3Department of Intensive Care, Hopital Erasme, Université Libre de Bruxelles
(ULB), Route de Lennik, 808, Bruxelles 1070, Belgium
Full list of author information is available at the end of the article
© 2013 Nordberg et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordefibrillated (e.g., pulseless electrical activity, PEA, and
asystole) [2-4]. Even fewer of these patients are alive on
hospital admission and most of them will eventually die
because of extended post-anoxic brain injury [5-8].
In 2002, two randomized clinical trials demonstrated
the benefit of therapeutic hypothermia (TH) on neuro-
logically intact survival in patients who were cooled in-
hospital for 12 to 24 hours to 32-34°C within few hours
from ROSC following an out-of-hospital cardiac arrest
(OHCA) with ventricular fibrillation (VF) or ventricular
tachycardia (VT) as first rhythm [9,10]. Based on these
studies, the International Liaison Committee on Resusci-
tation have recommended the use of TH as a routineral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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during post-resuscitation care. Despite the absence of
randomised trials, current guidelines recommend that
TH should be considered also in patients presenting with
non-shockable rhythms [11]. In addition, these guidelines
stated that patients resuscitated from OHCA should be
cooled as soon as possible; however, the optimal timing to
initiate TH in this setting remains unknown.
Several clinical studies have assessed the impact of
early cooling using cold saline infusion shortly after re-
turn of spontaneous circulation (ROSC). In 2007, Kim
et al. performed a feasibility study in 123 patients, which
demonstrated that early use of cold fluids was safe and
that the core temperature could be lowered 1.2 degrees
upon arrival to hospital. Also, there was a trend towards
increased survival to discharge in patients with VF/VT
[8]. Recently Bernard et al. published a randomized trial
on post-ROSC early cooling with cold fluids compared
to in-hospital TH in 234 VF-patients. Rapid cooling de-
creased core temperature of patients at hospital arrival
but did not improve outcome at hospital discharge com-
pared with cooling commenced in the hospital [12].
Recent data suggested that initiating TH during CPR,
before the reperfusion phase, would provide additional
beneficial effects against post-anoxic brain injury. Ani-
mal studies have shown that cooling induced during
CPR and prior to ROSC, the so-called “intra-arrest
hypothermia” (IATH), improved neurological outcome
when compared to animals that are cooled post-ROSC
[13-17]. To date, there are no sufficiently large human
studies that have evaluated the effects IATH compared
to standard TH initiated in-hospital on neurological
outcome and mortality [18]. In a retrospective analysis of
542 patients where 208 were treated with intra-arrest cold
intravenous fluids, the use of IATH associated with im-
proved ROSC rate but not with increased overall survival
to hospital discharge [19]. Importantly, only 13% of the
whole cohort received in-hospital TH.
Nevertheless, not all methods to induce IATH may
produce the same effects on brain recovery after CA. In
animal studies, global IATH has been induced by various
techniques/devices, including ice packs, intravascular
catheters, cold metal plates or total lung ventilation with
perfluorocarbons (PFC). Moreover, some devices may se-
lectively cool the brain primarily with less effect on core
body temperature and thus more rapidly protect cerebral
cells from ischemia/reperfusion injury. Only three experi-
mental studies have compared different IATH techniques
on specific outcomes [20-22]. Interestingly, cardiac func-
tion was significantly improved by IATH induced by an
intravascular system compared to cold fluids [20]; in this
study, IATH using cold fluids resulted in a lower coronary
perfusion pressure, a greater need for epinephrine and a
longer duration of CPR. In another study, PFC-total lungventilation achieved more easily ROSC than intra-arrest
cold fluids [21]. Finally, in a model of prolonged CA,
trans-nasal evaporative cooling (TNEC) initiated during
CPR improved the success of resuscitation compared with
IATH induced by cold fluids and reduced the duration of
CPR [18]. These studies supported the concept that IATH
induced by cold fluids may have some deleterious effects
on cardiac perfusion during CPR and may not as effective
as other techniques to reduce brain injury and improve
survival after CA.
TNEC is a method that has been developed to rapidly
induce IATH and achieve hypothermia for human CA.
The technique takes advantage of the nose as a natural
orifice into the head to overcome the obstacle of cooling
through the skull. The upper nasal pathways provide a
large diffuse surface area and vascularity that is in close
proximity to the cerebral circulation. Cooling in the
nasopharynx also offers the ability to cool via direct con-
ductive mechanisms that do not rely on spontaneous cir-
culation [22]. In the only randomized study using such
approach to induce IATH [23], 200 OHCA patients were
randomized during CPR, irrespective of their rhythm, to
receive either TNEC or standard of care (including post-
ROSC cooling at hospital). This feasibility study showed
that the method was safe for pre-hospital use. Overall
survival rates were similar in the two groups (15% vs.
13%). Among patients admitted to the hospital, overall
survival to hospital discharge was improved, although
not significantly, during IATH (44% vs. 31%, p = 0.16). In
the post-hoc analysis, the sub-group of patients with
time to CPR less than 10 minutes had an increased sur-
vival rate when treated by IATH (56% vs. 29%, p = 0.04).
Also, TNEC increased, although not significantly (p = 0.14),
the intact neurological outcome rate from 21% to 34%
when compared to the control group; these beneficial
effects were more pronounced in the subgroup of pa-
tients with time to CPR less than 10 minutes (43% vs. 17%,
p = 0.03).
Given these supportive data, we are conducting a ran-
domized controlled trial comparing TNEC to conventional
post-ROSC cooling. The aim is to determine whether
TNEC used during CPR would improve neurological out-
come in patients being resuscitated from OHCA and with
a time to CPR less than 15 minutes.
Methods/design
Study design
This is a prospective, multi-centre, randomized, single-
blind, controlled study conducted by the emergency re-
sponders of different emergency medical systems (EMS).
In the treatment arm, patients will be immediately cooled
by paramedics and/or emergency physicians using the
RhinoChill device. Intra-arrest cooling will be continued
after ROSC and until hospital admission for patients who
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of CPR in case of unsuccessful resuscitation. In the control
arm, patients will receive standard of care and will be
treated with TH after arrival at the hospital.
Study sites
The sites including patients in this study are: a) Karolinska
Institutet (Stockholm, Sweden), defined as the Principal
Investigator (PI); b) Hôpital Erasme (Brussels, Belgium);
c) Universiteit Ziekenhuis Leuven (Leuven, Belgium);
d) Emergency Medical Services of the Hradec Kralove
Region (Hradec Kraklove, Czech Republic). In Belgium
and Czech Republic, physicians will enroll patients while
in Sweden both physicians and paramedics will recruit
patients.
Inclusion/exclusion criteria
All victims of CA will be screened for study eligibility
upon arrival of the first responding team. Inclusion criteria
are: age ≥ 18 years; witnessed (heard or seen) collapse; not
having a pulse. Exclusion criteria are: age ≥ 80 years; eti-
ology of cardiac arrest due to trauma, severe bleeding, drug
overdose, cerebrovascular accident, drowning, smoke
inhalation, electrocution, hanging; already hypothermic
(≤ 34°C at tympanic or rectal temperature); an obvious
barrier to placing intra-nasal catheters (i.e., intranasal
obstruction); Do Not Attempt to Resuscitate (DNAR)
orders or terminal disease; known or clinically apparent
pregnancy; known coagulopathy (except therapeutically
induced); chronic oxygen therapy at home; response time
(call to first EMS CPR) > 15 minutes.
Randomization
Randomization will be carried out in blocks of four and
each site will be given sets of sequentially numbered
envelopes with randomization assignments provided in a
1:1 manner to distribute to the participating pre-hospital
vehicles. Individual envelopes will be placed in each
RhinoChill pack at the time of site initiation, and re-
placed as patients are enrolled. The RhinoChill pack will
be carried to every potential subject, and the envelope
will be opened once the subject has been qualified as
meeting all inclusion and exclusion criteria. Neither EMS
or hospital personnel will be blinded to treatment, since
the control patients are easily distinguishable from pa-
tients undergoing device placement and nasal cooling.
However, medical personnel making the final neuro-
logical assessment of the patient prior to discharge will
be blinded to patient’s group assignment.
Study treatment
The resuscitation attempt will follow current guidelines
[24] to the greatest extent possible. After airway man-
agement (i.e. laryngeal mask or intubation), patients arerandomized to early cooling or standard care. In patients
randomized to early cooling, the RhinoChill catheters
should be placed and cooling initiated immediately. To
place the nasal catheters and start cooling takes ap-
proximately 1 minute. Cooling should be performed
with the oxygen flow set to 40 L/min. There should
be no changes to the care received by patients randomized
to the control arm. Resuscitation attempts should be con-
tinued for at least 30 minutes after EMS arrive on the
scene in all patients before deciding that further interven-
tions are futile.
Device description
The RhinoChill works by spraying a liquid coolant onto
the upper surface of the nasal cavity, where it evaporates
and absorbs heat from the tissue, thereby cooling the tis-
sue and the innate vasculature that supplies blood to the
brain. The coolant is an inert liquid (perfluorohexane,
PFH) at one atmosphere of pressure and can carry 20
times more oxygen than saline. It has a surface tension
that is lower than water so it will spread uniformly and
quickly throughout the space in which it is sprayed. Oxy-
gen or air is delivered with the liquid coolant to maximize
its evaporation. Medical grade oxygen or breathing air
with a supply pressure of 60 psi and sufficient quantity to
provide a 40 L/min flow rate over the treatment period is
required in order to operate the RhinoChill.
The coolant vapor, along with the gas, escapes the
nasal cavity through the nostrils or the mouth. In the
event that all the coolant is not evaporated, it is possible
that it will either trickle out of the nostrils or trickle
down the pharynx into the mouth or stomach. Because
the coolant is immiscible in water, it is not absorbed in
any significant quantity into the body. The minute quan-
tities that may be absorbed into the blood or inhaled
into the lungs are expired through the lungs in a rela-
tively short period. Local temperatures within the nasal
cavity are expected to cool to around 2°C.
The RhinoChill consists of three components: the tub-
ing set, the control unit, and the coolant bottle. The tub-
ing set is a single-use device that delivers the pressurized
gas and coolant mixture to the patient. The proximal end
attaches to the control unit to which a medical gas source
is connected. Distal to the control unit is the interface for
the coolant bottle; this consists of a dip tube connected to
a bottle interface collar into which is incorporated a liquid
flow indicator. Liquid coolant is driven out of the bottle by
the pressurized gas, through a 0.22 μm filter, and then the
gas and coolant are delivered to the nasal catheters. The
trans-nasal catheters are joined together with a hub at the
proximal ends; the catheters are mated to the gas and li-
quid delivery lines via an integral manifold. The catheters
have separate gas and liquid capillaries that converge at
each of 12 spray ports along the dorsal surface of the
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ized gas at each of the spray ports results in efficient nebu-
lization of the vapor from each of these ports. Each
catheter also has three pressure sensing ports along the
ventral surface of the catheter that transmit the local pres-
sure in the nasal cavity to the control unit. The control
unit also has a mechanical over-pressure safety valve,
which is designed to vent excess oxygen to prevent a pres-
sure greater than 60 psi from entering the device.
The coolant bottle holds 1 liter of the evaporative
coolant that will last 30 minutes when the oxygen or air
flow rate is set to 40 L/min. The RhinoChill is config-
ured for use in a stable hospital setting (e.g., hanging
from an I.V. pole mount) or packaged in a backpack that
integrates a 3 L (900 liters gas) oxygen or air bottle, and
weighs approximately 9 kgs for use in the ambulance
and field setting. It is expected that at least one tubing
set and 1 L of coolant will be needed for each subject
enrolled in the early cooling arm. Patients that are resus-
citated after RhinoChill cooling is initiated will likely re-
quire 1–2 additional bottles of coolant before in-hospital
cooling can be initiated.
Post-resuscitation care
Return of spontaneous circulation will be defined as
obtaining an organized rhythm and palpable pulse sus-
tained for 20 minutes. Once an organized rhythm and
palpable pulse is achieved, subjects will have their
temperature taken via the tympanic route, stabilized and
then be transported to the hospital. If a patient wakes up
after ROSC is achieved, cooling will be discontinued; on
the opposite, subjects will, if needed be intravenously
administered bolus doses of sedation and analgesia for
transport to the hospital. Doses of sedation and analgesia
will be dictated by the institutional standard cooling
protocol. The oxygen supply in the transport vehicle
should be used to continue RhinoChill cooling during
transport to the hospital. Normal transport procedures
will be used for patients randomized to the control arm.
Infusions of cold saline or cooling with cold packs will not
be permitted in the pre-hospital setting for either group.
Upon hospital arrival, a systemic temperature probe will be
placed (i.e., bladder, arterial, rectal) and core temperature
will be recorded. Systemic hypothermia on arrival at Inten-
sive Care Unit (ICU) for both patient groups (treatment
and control) will be performed as follows:
– Duration of hypothermia for at least 24 hours.
– Target temperature 33°C ± 1°C.
– Recording of core- and tympanic temperature every
15 minute during the induction period (i.e., until
target temperature is reached).
– Rewarming rate at 0.2-0.5°C / hour.
– Control of post-cooling hyperthermia.Subjects randomized to the early cooling group with
the RhinoChill shall continue being cooled with the
RhinoChill until systemic cooling procedures can be
started. Intravenous sedation, analgesia and neuromuscu-
lar blockade (if used) should be initiated upon hospital ar-
rival according to institutional cooling protocols. Doses
should be adjusted as necessary over the course of cooling/
re-warming. After the subject has been prepared with the
standard hypothermia device, the RhinoChill should
be turned off, but the intranasal catheters should be left
in place while transitioning the subject to the standard
hypothermia protocol.
Intermittent activation of the RhinoChill may be con-
sidered if the core temperature does not continue to
drop via the systemic cooling method. Cooling via the
RhinoChill system will be halted immediately if any adverse
event related to the use of the RhinoChill develops.
For those patients in the control group, the standard
cooling procedure will be started as soon as practical.
Intravenous sedation, analgesia and neuromuscular block-
ade (if used) should be initiated upon hospital arrival
according to institutional cooling protocols. Doses should
be adjusted as necessary over the course of cooling/re-
warming. Temperatures (tympanic and core) will be moni-
tored periodically over the first 48 hours after hospital
arrival for all patients. ECG, peripheral oxygen saturation,
heart rate and blood pressure monitoring will continue
throughout the acute care period. Ventilation settings
should be adjusted to maintain arterial oxygen saturation
94-98% (e.g., PaO2 80–120 mmHg) and normocapnia
(e.g., PaCO2 35-45 mmHg). A positive end-expiratory
pressure (PEEP) level should be adjusted to reduce FiO2
below 60%, whenever possible. Electrolytes will be subs-
tituted as necessary to maintain normal ranges. Blood pres-
sure should be kept above 65 mmHg at all times. Drops in
pressure should be treated primarily with crystalloid fluids.
If sufficient pressure control cannot be achieved with fluids
alone, vasopressor drugs, such as adrenaline or norepin-
ephrine, should be used. Serum blood glucose should be
kept between 110 and 150 mg/dl with insulin admin-
istration. Enteral feeding will be initiated according to
local guidelines.
Data collection
Data collection concerning the cardiac arrest will include
time to collapse; bystander CPR; location; time of arrival
of basic and advanced life support, ALS, teams; time of
emergency call; time of first emergency medical team
initiated CPR, patient characteristics (i.e. gender, weight,
age, comorbidities), resuscitation effort (time CPR is ini-
tiated by the first emergency medical staff, EMS, re-
sponder; time cooling initiated - if cooled; mechanical
CPR, if not manual; time intravenous access obtained;
first rhythm; total adrenaline/epinephrine dose; shock
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dose(s); time airway is secured; recurrent VF or re-
arrest; time randomized; time ROSC or death declared).
Also, quality of CPR, including the number and depth of
chest compressions/min as well as CPR hands-off time,
will be recorded whenever possible. After hospital ad-
mission, tympanic temperature; heart rate, peripheral
oxygen saturation (SpO2), mean arterial pressure, end-
tidal carbon dioxide (EtCO2), arterial blood gas analysis,
initial ECG findings and Glasgow coma score will be re-
corded. Concomitant interventions (e.g., coronary angio-
gram, aortic balloon pump, bypass surgery, internal cardiac
defibrillator placement) will also be recorded. The systemic
cooling procedures, including the system used, the core
temperature location, the duration and the hypothermia
reversal algorithm will be recorded.
The Steering Committee has the responsibility to per-
form periodic and spot checks visits to monitor the pro-
gress of the clinical study. Completed Case Report Forms
(CRFs) will be reviewed for completeness, compliance
with the investigation plan, and appropriate device use
and accountability. Case Report Forms will be provided to
each site for each subject enrolled in the study. Required
data concerning patient treatment and test results will be
recorded on the CRFs at the time of the procedure or as
soon as possible thereafter. Information recorded in the
CRFs will be corroborated by data in the subject’s medical
records. Completed and monitored CRFs will be uploaded
on a website developed by the PI, which will be overseeing
data entry and data quality management. Data on safety
will be provided to the Steering Committee with regular
time intervals.
The Steering Committee will review study integrity,
safety and risk/benefit issues at periodic intervals through-
out the study. The frequency of these reviews will be
dependent upon the rate of patient enrollment and rele-
vant safety issues. Independent analyses of serious adverse
events will be performed and adjudicated if the frequency
or nature of serious adverse events warrants it.
Follow-up
Subjects treated with the RhinoChill will undergo rhino-
scopic examination of the nasal cavity if it is warranted
based on clinical signs of intra-nasal trauma (e.g., bleed-
ing from the nostrils, whitening of the nose or other
treatment-related observations). All patients still alive
will undergo a neurological examination 72 hours after
hospital admission. Neurological status will be classified
using the Cerebral Performance Category (CPC) [25].
Subjects will be followed until death or at 90 days. The
following data will be recorded concerning their hospital
course: date/time subject wakes; date/time subject is
taken off ventilator; date/time subject is discharged from
ICU; date/time subject dies (if in hospital); date/timesubject is discharged from hospital; discharge dispos-
ition; CPC at hospital discharge. CPC will be evaluated
at 90 days through a telephone interview by an inde-
pendent physician using the Glasgow Outcome Scale
(GOS) and the 15D instrument. If there are difficulties
in CPC-classification, the patient will be assessed by a
neurologist at an out-clinic visit. Clinically significant
serious adverse events will be recorded from the time
ROSC is achieved through the earliest of the following
three events: death, hospital discharge, or one week fol-
lowing admission. The nature and severity of the adverse
event, the relationship to the RhinoChill Device, man-
agement and outcome will be recorded on the CRF.
Study outcomes
The main objective of this study is to assess the impact
on neurological intact survival rates at 90 days of trans-
nasal IATH compared to standard treatment. Thus, the
primary end-point will be the neurological intact sur-
vival rates (i.e. patients with CPC score of 1–2) at 90 days
after arrest among all those admitted to the hospital.
Secondary end-points will include:
– Overall survival at 90 days among patients admitted
to the hospital.
– Survival and neurological intact outcome at 90 days
among all included patients.
– ROSC rate.
– Survival to hospital admission.
– Proportion of patients reaching target temperature
(≤ 34° Celsius) within 4 hours of call to dispatcher.
– All adverse events occurring within 24 hours of
beginning ALS procedures.
– Serious adverse events (SAE) from the time of
patient randomization through the first seven days
of hospitalization.
Importantly, in the cases where withdraw of life
support is decided due to poor prognosis, the reasons
must be clearly stated in the CRF, as well as results of
neurological examination or additional tools (i.e. brain
imaging, biomarkers, electroencephalography, somato-
sensory evoked potentials - SSEPs), which are used.
No specific recommendation on post-anoxic coma
prognostication has been provided in this study.
Statistical analysis
The primary outcome measure of this study is neurological
intact survival at 90 days among all patients admitted to
the hospital. Considering data from the previous trial [23],
we postulated that the using of IATH with TNEC tech-
nique could improve this primary outcome from 21% to
37%. For a 80% power and α error of 0.05, the study re-
quires 150 patients admitted to the hospital who should be
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rate around 40% and 10% of lost to follow-up, the study
will require a sample size of 418 patients for each arm (836
in total), regardless of initial rhythm. Analysis of data will
be based on “Intention-to-treat”. A first interim analysis
will be performed after 200 patients; conditional power for
meeting the primary endpoint will be, if needed, recalcu-
lated at that time, and if the interim results do not corres-
pond to the primary end-point, termination of the study
for futility will be considered. In case of sample calculation
exceeding 500 patients, other potential recruiting centers
will be included in the study. Other interim analyses will
be performed each 200 patients included. Early stopping
for efficacy reasons will only be considered if major out-
come differences are seen between the groups according to
the Haybittle rule with a p-value ≤ 0.001.
Stratified analyses will be performed for patients
whose first recorded rhythm is VF/VT versus those in
whom the first recorded rhythm is PEA/asystole. Sub-
group analyses will be performed for subjects where
CPR was initiated within 10 minutes by a first EMS re-
sponse team or where cooling was started within 15 mi-
nutes. The study is expected to last until 2016.
Consent/ethics
Because inclusion is decided as soon as possible after
EMS arrival, informed consent cannot be obtained be-
fore enrollment into the study, but deferred consent will
be obtained in each case. The RhinoChill device has
received CE marking and did not raise any major safety
issues in previous studies [23,26]; as such, local Ethics
Committees (The Regional Ethical Review Board in
Stockholm - reference study number: 2010/383-32; Comité
d’Ethique de l’Hôpital Erasme – reference study number:
P2012/321; Ethics Committee, University Hospital Hradec
Kralove –reference study number: 201204 S24ZP; Com-
missie Medische Ethiek van Universitaire Ziekenhuizen
KU Leuven; reference study number: S54255) approved
study in eligible patients who are unable to provide con-
sent prior to their treatment, as they will necessarily be co-
matose. Ethical consideration for treating subjects without
their express consent is in accordance with the World
Medical Association Helsinki Declaration of 1964, as re-
vised at the 59th General Assembly in Seoul in 2008. For
subjects admitted to the hospital after ROSC, their legal
representative will be informed of the study as soon as pos-
sible and must approve for data collection and continu-
ation of the study. Subjects who will show neurological
recovery will be informed of their study participation and
be asked to provide their consent for the use of their data.
Data safety management
The Data Safety Monitoring Committee (DSMC) is con-
stituted and will review data every 3 months. Given thatit is expected that more than half of the patients will die
at the scene or during the hospital stay, and that recur-
rent cardiac arrest at any time is possible with standard
care, it is not considered appropriate to report every
death to the DSMC as a serious adverse effect. Sites will
report all SAEs that occur within 7 days of enrollment
directly to DMSC. A “technical device failure” is defined
as a failure of the device to perform its intended func-
tion when used in accordance with the instructions for
use. Technical device failures will be recorded and evalu-
ated for possible untoward effects on the subject. All
clinically significant AEs or those that appear to be re-
lated to the use of the RhinoChill (i.e., whitening of the
nose; epistaxis; mucosal irritation/dryness; para-sinus
emphysema) as well as those that could potentially harm
the patient (i.e., pleural effusion) will be recorded on the
CRF from ROSC through the end of the cooling period.
Discussion
The most common limitation in CA studies is the lack
of either pre-hospital or in-hospital standardised proto-
cols to manage these patients. This also applies to TH.
Most studies on cooling after CA were limited to the
in-hospital setting, where patients were treated after ad-
mission to the Emergency Department or ICU and evalu-
ation of outcome is restricted to hospital discharge and
corrected for several in-hospital factors [27,28]. This ap-
proach may of course create different confounders; indeed,
pre-hospital factors have a significant impact on survival
of resuscitated patients and the presence of different types
of EMS may provide unbalanced quality of CPR and
pre-hospital care that could later affect the measured
outcomes [29,30]. On the other hand, pre-hospital studies
generally lacked a standardised in-hospital management
of these patients while post-resuscitation care can also
substantially alter neurological recovery after anoxic injury
[19,31]. Moreover, in some studies, cooling was also inter-
rupted after hospital arrival, thus limiting its potential
benefits [19]. These are all important issues to consider
when discussing the optimal time to start TH after CA.
The importance of this trial is the comprehensive
approach where the whole chain of factors and manage-
ment of the patient is investigated. This is indeed the
largest trial investigating a brain selective cooling ap-
proach, initiated in the pre-hospital setting, and involv-
ing numerous people in the treatment of such patients
from the field until ICU admission. The rationale behind
the PRINCESS study is to confirm the promising results
observed in the PRINCE trial, although with the ambi-
tion to improve the management of the patients in terms
of earlier initiation of cooling, limited cooling interruptions
from the pre-hospital to the in-hospital setting, a standar-
dised in-hospital management and a longer follow-up
period for improved neurological evaluation. Importantly,
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the use of TNEC and patients management should be as
standardised as possible. The risk of having many centres
with low inclusion rate and poor skills with Rhinochill use
may influence the final results.
Few data are available on the optimal timing to initiate
TH after CA. The PRINCESS study will test the effect of
TNEC during CPR on patient neurologically intact sur-
vival when compared to standard in-hospital cooling. If
brain selective cooling will improve brain recovery after
anoxic injury, an important improvement in the pre-
hospital management of such patients will be obtained.Abbreviations
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